• 

  Adar Poonawalla likely to meet Health Minister Mansukh Mandaviya tomorrow

  India | August 05, 2021 18:42 IST

  Adar Poonawalla, CEO-Owner of the Pune-based Serum Institute of India (SII), is expected to meet Union Health Minister Mansukh Mandaviya in Delhi on Friday.

• 

  Adar Poonawalla sets aside Rs 10 crore to support students travelling abroad

  India | August 05, 2021 12:34 IST

  ​Serum Institute of India CEO and owner Adar Poonawalla on Thursday said that he has set aside Rs 10 crore to support students travelling abroad for studies, as a few countries are yet to approve Covishield as an acceptable vaccine for entry without quarantine.  

• 

  Good News: Poonawalla after 16 European nations recognise Covishield

  India | July 18, 2021 9:33 IST

  The issue of the acceptance of the Covishield vaccine as proof of immunisation for travel to the EU Member States has been widely discussed recently, after several countries in the block have refused to recognise the vaccine.

• 

  Confident Covishield will get EMA approval in a month: Adar Poonawalla

  India | June 30, 2021 19:52 IST

  We are quite confident that in a month EMA will approve Covishield. There is no reason why not to, because it is based on AstraZeneca data and our product is identical to AstraZeneca more or less and it has been approved by WHO, UK MHRA, Adar Poonawalla said.

• 

  Hope to resolve issues faced by Indians vaccinated with Covishield travelling to EU soon: Poonawalla

  India | June 28, 2021 13:08 IST

  Covishield is the Oxford University-AstraZeneca vaccine manufactured in India by the Pune-based vaccine maker.  

• 

  'Will boost vaccine production': Poonawalla thanks Jaishankar, Biden for policy change

  India | June 05, 2021 0:06 IST

  Serum Institute of India (SII) CEO Adar Poonawalla has thanked US President Joe Biden, External Affairs Minister S Jaishankar for policy change with respect to raw material needed for vaccine production saying it will boost manufacturing and strengthen fight against Covid.

• 

  Serum Institute of India seeks indemnity against liabilities: Sources

  India | June 03, 2021 10:15 IST

  India has so far not given any manufacturer of a Covid-19 vaccine indemnity against the costs of compensation for any severe side effects.

• 

  Global supply of COVAX hit due to coronavirus crisis in India, USAID tells lawmakers

  World | May 28, 2021 8:14 IST

  There are many parts of the world where one shot has been dispensed to health workers or frontline workers and the second shot has not been forthcoming, USAID told lawmakers on Thursday.

• 

  'Never exported vaccines at the cost of people in India': Adar Poonawalla

  India | May 19, 2021 0:05 IST

  Serum Institute of India (SII) CEO Adar Poonawalla said that vaccination in a large populous country such as India won't be possible in 2-3 months.

• 

  WHO reminds Serum Institute of its COVAX commitments amidst devastating COVID-19 outbreak

  Business | May 18, 2021 11:10 IST

  WHO chief Tedros Adhanom Ghebreyesus has said that once the devastating COVID-19 outbreak in India recedes, the Serum Institute of India will need to “get back on track and catch up” on its delivery commitments to COVAX, the global initiative to supply coronavirus vaccines to nations around the world.

• 

  Adar Poonawalla to deliver 1.5 crore doses of Covishield to Maharashtra: Rajesh Tope

  India | May 13, 2021 12:17 IST

  The Maharashtra state cabinet held a meeting on Wednesday to discuss the Covid management.

Advertisement
• 

  Give priority to Maharashtra in vaccine allocation: Health Minister Rajesh Tope to Serum CEO

  India | May 03, 2021 23:58 IST

  Maharashtra Health Minister Rajesh Tope on Monday urged Serum Institute of India Chief Executive Officer Adar Poonawalla to give priority to the state in providing its anti-coronavirus vaccine as the government was ready to purchase doses from the Pune-based company.

• 

  Working closely with govt, got all kinds of support: Adar Poonawalla on vaccine production

  India | May 03, 2021 17:02 IST

  Serum Institute of India (SII) CEO Adar Poonawalla has issued a statement regarding vaccine availability in the country and ramping up its production. SII issued Poonawalla's statement after some of his comments on vaccine production were misinterpreted.

• 

  Covishield production in full swing in Pune, will return to India soon, says Adar Poonawalla

  India | May 02, 2021 9:37 IST

  Serum Institute of India CEO Aadar Poonawalla has said that the production of COVID-19 vaccine Covishield is in full swing in Pune and he will review the operations once he is back in the country.

• 

  Adar Poonawalla, Serum Institute CEO, to get 'Y' category security

  India | April 28, 2021 20:05 IST

  According to the Home ministry's order, Poonawalla will be provided security by the Central Reserve Police Force (CRPF) wherever he travels in India.

• 

  Covishield price for states reduced from Rs 400 to Rs 300 per dose, Adar Poonawalla tweets

  India | April 29, 2021 0:01 IST

  Serum Institute of India's CEO Adar Poonawalla on on Wednesday tweeted that the revised price will be effective immediately.

• 

  Private hospitals to get limited portion of Covishield at Rs 600 per dose: SII

  India | April 24, 2021 19:12 IST

  The Serum Institute of India (SII) on Saturday said only a limited portion of its vaccines volume will be sold to private hospitals at Rs 600 per dose.

• 

  BJP MLA slams SII over anti-COVID vaccine pricing, calls its CEO Adar Poonawalla 'dacoit'

  India | April 22, 2021 16:55 IST

  Gorakhpur MLA Dr Radha Mohan Das Agrawal made the remarks after SII on Wednesday announced a price of Rs 600 per dose for Covishield supplies to private hospitals and Rs 400 per dose to state govts.

• 

  'Respected POTUS...': Adar Poonawalla urges US Prez to lift embargo on vaccine raw material exports

  India | April 16, 2021 16:47 IST

  Serum Institute of India (SII) CEO Adar Poonawalla has urged US President Joe Biden to lift the embargo of raw material exports for the vaccine industry outside the United States so that the vaccine production can ramp up.

• 

  AstraZeneca legal notice to Serum Institute over delays

  India | April 08, 2021 9:34 IST

  Poonawalla has mentioned that the existing production capacity to manufacture Covishield in India is under pressure due to increased demand in India.